Literature DB >> 32269001

Treatment of oral ranula in HIV-positive patient.

Yusuke Kusano1, Ryoukichi Ikeda1, Yutaro Saito1, Muneharu Yamazaki1, Yutaka Tateda1, Shiori Kitaya1, Fumi Shoji1, Takahiro Suzuki1, Naoya Noguchi1, Masafumi Seki2, Nobuo Ohta3.   

Abstract

HIV-associated salivary gland disease refers to the pathology in head and neck lesions such as ranula, salivary gland swelling, xerostomia, and benign lymphoepithelial cysts in the parotid gland. Here, we present a unique case of the ranula patient with HIV infection treated with OK-423 sclerotherapy. Case report: The patient was a 42-year-old Japanese male with a few months history of oral floor swelling. Computed tomography (CT) showed a low-density area limited within the right floor of the mouth. Magnetic resonance imaging (MRI) revealed a distinct T2-high intensity area localized on the same location. The puncture fluid was bloody mucus, and the cytology was no malignancy. We diagnosed a simple ranula. He was, however, found to be HIV-antibody positive at the examination before treatment by chance. He was referred to the department of infectious diseases and definitively diagnosed HIV infection by western blot. We chose OK-432 sclerotherapy because of its minimally invasive and the risk of HIV infecting medical staff. Two times OK-432 injection made the lesion disappear.
Conclusion: The case indicated that OK-432 sclerotherapy could be effective for ranula related to HIV.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  HIV-associated salivary gland disease; Human immunodeficiency virus (HIV); OK-423 sclerotherapy; Ranula; Sclerotherapy

Year:  2020        PMID: 32269001     DOI: 10.1016/j.anl.2020.02.009

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  1 in total

1.  OK-432 Treatment of Ranula Intruding into the Cervical Region.

Authors:  Nobuo Ohta; Shion Shirane; Shigeru Fukase; Rei Kawata; Teruyuki Sato; Nozomi Satani; Takahiro Suzuki
Journal:  Clin Pract       Date:  2022-03-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.